Boston Scientific Takeover Talks Cause SWAV Stock to Plummet.
The potential deal between Boston Scientific and Shockwave Medical reportedly fell apart due to disagreement on price, causing Shockwave's stock to drop by 6.3%. The deal could have bolstered Boston Scientific's cardiovascular portfolio with Shockwave's intravascular lithotripsy technology. Shockwave is expected to report a 103% increase in earnings and a 57% increase in sales for Q1. Analysts predict Shockwave's earnings to increase by 35% and sales to surge by 37% for the year.